ResearcherSapporo Medical UniversityNo recent work listed
Norimasa Sawada
Matched on OpenAlex author ID A5111517830, A5112097475. Sources: OpenAlex.
Their work
- Papers
- 9 (first author 0, last author 7)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 11
2011: 3 papers · 2012: 2 papers · 2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 1 paper
Papers 9
- Nuclear localization of tricellulin promotes the oncogenic property of pancreatic cancer. Last author DOI 10.1038/srep33582↗
- Claudin-4 binder C-CPE 194 enhances effects of anticancer agents on pancreatic cancer cell lines via a MAPK pathway. Co-author DOI 10.1002/prp2.196↗
- c-Jun N-terminal kinase inhibitor SP600125 enhances barrier function and elongation of human pancreatic cancer cell line HPAC in a Ca-switch model. Co-author DOI 10.1007/s00418-014-1300-4↗
- Protein kinase Cα inhibitor protects against downregulation of claudin-1 during epithelial-mesenchymal transition of pancreatic cancer. Last author DOI 10.1093/carcin/bgt057↗
- Expression of claudins 7 and 18 in pancreatic ductal adenocarcinoma: association with features of differentiation. Last author DOI 10.1136/jclinpath-2011-200400↗
- Targeting claudin-4 in human pancreatic cancer. Last author DOI 10.1517/14728222.2012.708340↗
- Transcriptional regulation of claudin-18 via specific protein kinase C signaling pathways and modification of DNA methylation in human pancreatic cancer cells. Last author DOI 10.1002/jcb.23095↗
- Protein kinase Cα inhibitor enhances the sensitivity of human pancreatic cancer HPAC cells to Clostridium perfringens enterotoxin via claudin-4. Last author DOI 10.1007/s00441-011-1287-2↗
- Downregulation of tight junction-associated MARVEL protein marvelD3 during epithelial-mesenchymal transition in human pancreatic cancer cells. Last author DOI 10.1016/j.yexcr.2011.06.020↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Takashi Kojima · 9 shared papers, 2011–2016 · strength 0.35
- Paper c-Jun N-terminal kinase inhibitor SP600125 enhances barrier function and elongation of human pancreatic cancer cell lin… DOI 10.1007/s00418-014-1300-4↗
- Paper Nuclear localization of tricellulin promotes the oncogenic property of pancreatic cancer. DOI 10.1038/srep33582↗
- Paper Targeting claudin-4 in human pancreatic cancer. DOI 10.1517/14728222.2012.708340↗
- Koichi Hirata · 6 shared papers, 2011–2016 · strength 0.21
- Paper Nuclear localization of tricellulin promotes the oncogenic property of pancreatic cancer. DOI 10.1038/srep33582↗
- Paper Claudin-4 binder C-CPE 194 enhances effects of anticancer agents on pancreatic cancer cell lines via a MAPK pathway. DOI 10.1002/prp2.196↗
- Paper Protein kinase Cα inhibitor protects against downregulation of claudin-1 during epithelial-mesenchymal transition of pa… DOI 10.1093/carcin/bgt057↗
- Daisuke Kyuno · 6 shared papers, 2011–2015 · strength 0.21
- Paper Targeting claudin-4 in human pancreatic cancer. DOI 10.1517/14728222.2012.708340↗
- Paper Claudin-4 binder C-CPE 194 enhances effects of anticancer agents on pancreatic cancer cell lines via a MAPK pathway. DOI 10.1002/prp2.196↗
- Paper Protein kinase Cα inhibitor protects against downregulation of claudin-1 during epithelial-mesenchymal transition of pa… DOI 10.1093/carcin/bgt057↗
- Akira Takasawa · 6 shared papers, 2011–2016 · strength 0.19
- Paper Nuclear localization of tricellulin promotes the oncogenic property of pancreatic cancer. DOI 10.1038/srep33582↗
- Paper Protein kinase Cα inhibitor protects against downregulation of claudin-1 during epithelial-mesenchymal transition of pa… DOI 10.1093/carcin/bgt057↗
- Paper Expression of claudins 7 and 18 in pancreatic ductal adenocarcinoma: association with features of differentiation. DOI 10.1136/jclinpath-2011-200400↗
- Tatsuya Ito · 5 shared papers, 2011–2015 · strength 0.15
- Paper Claudin-4 binder C-CPE 194 enhances effects of anticancer agents on pancreatic cancer cell lines via a MAPK pathway. DOI 10.1002/prp2.196↗
- Paper Protein kinase Cα inhibitor protects against downregulation of claudin-1 during epithelial-mesenchymal transition of pa… DOI 10.1093/carcin/bgt057↗
- Paper Protein kinase Cα inhibitor enhances the sensitivity of human pancreatic cancer HPAC cells to Clostridium perfringens e… DOI 10.1007/s00441-011-1287-2↗
- Takumi Konno · 2 shared papers, 2015 · strength 0.10
- Paper c-Jun N-terminal kinase inhibitor SP600125 enhances barrier function and elongation of human pancreatic cancer cell lin… DOI 10.1007/s00418-014-1300-4↗
- Paper Claudin-4 binder C-CPE 194 enhances effects of anticancer agents on pancreatic cancer cell lines via a MAPK pathway. DOI 10.1002/prp2.196↗
- Masafumi Imamura · 3 shared papers, 2011–2015 · strength 0.10
- Paper Claudin-4 binder C-CPE 194 enhances effects of anticancer agents on pancreatic cancer cell lines via a MAPK pathway. DOI 10.1002/prp2.196↗
- Paper Protein kinase Cα inhibitor protects against downregulation of claudin-1 during epithelial-mesenchymal transition of pa… DOI 10.1093/carcin/bgt057↗
- Paper Transcriptional regulation of claudin-18 via specific protein kinase C signaling pathways and modification of DNA methy… DOI 10.1002/jcb.23095↗
- Yasutoshi Kimura · 3 shared papers, 2011–2015 · strength 0.10
- Paper Claudin-4 binder C-CPE 194 enhances effects of anticancer agents on pancreatic cancer cell lines via a MAPK pathway. DOI 10.1002/prp2.196↗
- Paper Protein kinase Cα inhibitor protects against downregulation of claudin-1 during epithelial-mesenchymal transition of pa… DOI 10.1093/carcin/bgt057↗
- Paper Transcriptional regulation of claudin-18 via specific protein kinase C signaling pathways and modification of DNA methy… DOI 10.1002/jcb.23095↗
- Tsuyoshi Kono · 2 shared papers, 2015–2016 · strength 0.10
- Makoto Osanai · 1 shared paper, 2016 · strength 0.05
- Ylermi Soini · 1 shared paper, 2012 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.